We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diurnal Group Plc | LSE:DNL | London | Ordinary Share | GB00BDB6Q760 | ORD GBP0.05 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 27.30 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
24/2/2021 08:22 | And boom 10k sell. Woop woop | aimmafia | |
24/2/2021 08:14 | What are those MM playing at !! 15min and still 58/58p ....one MM on bid 1 on ask | tarlok | |
24/2/2021 04:50 | best I am on your page mate. | simon_64 | |
24/2/2021 00:12 | I’m in here and STX. DNL much more certain. The rise from 30p was decent so at least we’re in a new range now. Feels like another long consolidation period | siriusbizness | |
23/2/2021 17:04 | Well that depends on if you don’t expect any increase on back of Chronocort approval if successful but this news could fall anytime | best1467 | |
23/2/2021 15:24 | Mufprat has hit the nail on the head. Market wants to see revenue. That will come. No rush to buy more at this moment in time | jaspoland | |
23/2/2021 11:03 | ALL my small companies are down today. Carnage! Squeaky bum time. | bradders51 | |
23/2/2021 10:13 | Said it before will say it again. Revenues are the answer. A company can only go so far on potential. DNL appears to have reached the potential ceiling so once increasing revenue streams are reported the share price will break out. It's all coming together nicely. Chronocourt approvals will lead to rapid sales as the foundations are already in place of being out in place. | mufprat | |
23/2/2021 09:54 | Sorry over 90,000 | aimmafia | |
23/2/2021 09:51 | It's too cheap down here not to buy more | aimmafia | |
23/2/2021 09:49 | I've just taken the 11678 taking my holding to over 80,000 | aimmafia | |
23/2/2021 09:17 | Yes, STX - FDA approval July 19, no progress (unlike here), and 75% down atm ! Mr Market is running amok, have to keep telling myself it's all a test.... | daveboy19 | |
23/2/2021 09:16 | It’s extremely frustrating continued world wide rollout of ALK with Chronocort looking more likely than not to get Approval but it’s never a done deal. The only slight disappointment since the number of years I’ve been invested is the Last ALK numbers while I appreciate the Pandemic issues I was still expecting slightly stronger growth. Putting that aside the growth potential in the next number of years For ALK alone should more than support the current MCap and Chronocort approval likely and Ditest further down the line plus the interesting and slightly lost comment in today’s RNS regarding potential Expansion of the Label | best1467 | |
23/2/2021 08:58 | No, but that's life. | royalalbert | |
23/2/2021 08:55 | Any body know of a more unloved share..even with 2 x RNS that look good ...and price falls ? | tarlok | |
23/2/2021 08:55 | I'm waiting for the dip if it happened and have another £10k to add | aimmafia | |
23/2/2021 08:05 | As expected, need the volume. | royalalbert | |
23/2/2021 08:03 | pps and there he is....lol | tarlok | |
23/2/2021 08:02 | If we drop today I will 100% taking more after the boards confidence in the approval of chrono... GLA | aimmafia | |
23/2/2021 08:00 | Brilliant news all around revenues up in the middle of a pandemic. As Aim says they are stating approval is nailed on. | simon_64 | |
23/2/2021 07:57 | In addition, we are preparing for the next phase of development of DITEST(TM) in the US as an innovative, testosterone-based, potential treatment for hypogonadism and this is a major commercial opportunity within our pipeline of products." | frrinvest | |
23/2/2021 07:55 | ps So look for the seller to come right out at 61p bid ...just to make sure we dont move... | tarlok |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions